Mohammad Maher Abdul Hay, MD

About Me

Conditions and Treatments

leukemia, multiple myeloma (MM), non Hodgkin's lymphoma (NHL), Hodgkin disease (HD), CNS lymphoma, cutaneous t-cell lymphoma, AIDS-related lymphoma, anemia, platelet disorders, bleeding tendency


  • Assistant Professor, Department of Medicine
Board Certifications
  • American Board of Internal Medicine (Hematology), 2012
  • American Board of Internal Medicine (Medical Oncology), 2012
  • American Board of Internal Medicine - Internal Medicine, 2009
Education and Training
  • Fellowship, NYU School of Medicine, Hematology/Oncology, 2012
  • Residency, State University of NY at Buffalo, Internal Medicine, 2009
  • MD from American University - Beirut, 2004

Locations and Appointments

73 Insurance Plans Accepted
  • Aetna HMO
  • Aetna Indemnity
  • Aetna Medicare
  • Aetna POS
  • Aetna PPO/EPO
  • Affinity
  • Affinity Exchange- Essential
  • Agewell
  • Cigna EPO/POS
  • Cigna PPO
  • ElderPlan
  • Empire Blue Cross Blue Shield EPO
  • Empire Blue Cross Blue Shield HMO
  • Empire Blue Cross Blue Shield HealthPlus
  • Empire Blue Cross Blue Shield HealthPlus Essential
  • Empire Blue Cross Blue Shield Indemnity
  • Empire Blue Cross Blue Shield MediBlue
  • Empire Blue Cross Blue Shield POS
  • Empire Blue Cross Blue Shield PPO
  • Empire Blue Cross Blue Shield Pathways, Enhanced
  • Fidelis Child Health
  • Fidelis Essential
  • Fidelis Exchange
  • Fidelis Family Health
  • Fidelis Medicaid
  • Fidelis Medicare
  • HIP Access I
  • HIP Access II
  • HIP Child Health
  • HIP Medicare
  • HealthSmart (WTC)
  • Healthfirst
  • Healthfirst Essential
  • Hotel Trades
  • Humana Medicare
  • Independent Care System New York
  • Local 1199 PPO
  • MagnaCare PPO
  • Medicare
  • MetroPlus Child Health
  • MetroPlus Essential
  • MetroPlus Exchange Plans
  • MetroPlus Family Health
  • MetroPlus Medicaid
  • MetroPlus Medicare
  • MultiPlan/PHCS PPO
  • NY Medicaid
  • NYS Empire Plan
  • Oscar
  • Oxford Freedom
  • Oxford Liberty
  • Oxford Medicare
  • PHP
  • Tricare
  • UnitedHealthcare Community & State Plan
  • UnitedHealthcare Core and Charter
  • UnitedHealthcare EPO
  • UnitedHealthcare HMO
  • UnitedHealthcare Medicare
  • UnitedHealthcare POS
  • UnitedHealthcare PPO
  • UnitedHealthcare Top Tier
  • Village Caremax
  • Visiting Nurse Service (VNS) Medicare
  • WellCare Child Health
  • WellCare Family Health
  • WellCare Medicaid
  • WellCare Medicare
  • Wellcare Exchange
*Insurance listed above may not be accepted at all office locations. Please confirm prior to each visit. The information presented here may not be complete or may have been changed.
NYU Medical Oncology Associates

240 East 38th Street, 19th Floor
New York, NY 10016


Phone: 646-501-4818

Welcome back!

As a returning patient for this doctor, please schedule an appointment using your MyChart at NYU Langone account.

Learn more about MyChart at NYU Langone.

My Research

STAT3 contributes to several aspects of the malignant phenotype, including increased cell survival and proliferation and decreased host anti-tumor immunity in the tumor microenvironment. Up to 50% of AML patients display enhanced tyrosine phosphorylation of STAT3 and high expression levels of STAT3 correlate with poor treatment response in these patients. Also serine phosphorylation of STAT proteins in the absence of tyrosine phosphorylation and increased cytokine signaling has been implicated in human leukemia. We have been conducting experiments to better understand the role of STAT3 serine phosphorylation, the novel role of mitochondrial STAT3, STAT3 metabolic programing and its effect on glutathione (GSH) production. In addition we are testing STAT3 expression in myeloblasts obtained from AML patients and its cytogenetics/molecular correlations. Our target have been to aid in the design of cancer therapeutics that target STAT3 dependent processes and so far we have found enhanced Romidepsin (HDAC inhibitor) toxicity in STAT3-contiaining cancer cells and continue to test the involvement of regulated GSH synthesis in this process. We are in the process of exploring novel agents that target STAT3 in multiple hematological malignancies like multiple myeloma. Our studies hopefully will lead to have better treatments available in hematological malignancies through targeting STAT3.


  • 'Acute myeloid leukemia: a comprehensive review and 2016 update'

    De Kouchkovsky, I; Abdul-Hay, M
    Blood cancer journal. 2016 Jul 1. 6 (7): e441-e441 e441

  • Novel agents in the treatment of multiple myeloma: a review about the future

    Naymagon, Leonard; Abdul-Hay, Maher
    Journal of hematology & oncology. 2016. 9 (1): 52-52

  • A synthetic lethal interaction between glutathione synthesis and mitochondrial reactive oxygen species provides a tumor specific vulnerability dependent on STAT3

    Garama, Daniel J; Harris, Tiffany J; White, Christine L; Rossello, Fernando J; Abdul-Hay, Maher; Gough, Daniel J; Levy, David E
    Molecular & cellular biology. 2015 Aug 17. 35 (21): 3646-3656

Read All Publications (8)